BioMedReports | TalkMarkets | Page 3
Biotech Investing, Healthcare Stocks
Contributor's Links: BioMedReports
BioMedReports.com was co-founded by M.E. Garza and Mike Havrilla in early 2009. Both were successful traders and investors who had historically made some of their BEST TRADESmore

All Contributions

Latest Posts
33 to 48 of 77 Posts
AGIO Hits Record Level On Impressive Clinical Data For Leukemia Drug
Shares of Agios Pharmaceuticals Inc. posted its biggest single day rally on Wednesday since 26th September. The stock is up a whopping 15% to $96.25 after hitting an all time high of $96.88 earlier in the session.
ARWR Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi; TPIV Announces Phase II Clinical Trials With VGTI Florida
ARWR today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate.TPIV. is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida.
TapImmune Shares Gain 28% On Pending Catalysts And Published Comments By CEO
Shares of TapImmune, Inc. rose nearly 30% after the firm was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, PH.D.
CMRX Brincidofovir Selected For Use In Ebola Clinical Trial; AZN And ISIS To Co-Develop Targeted Oligonucleotide Delivery Methods
CMRX announced its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study with ebola. (ISIS) and (AZN) announced a strategic alliance to develop novel delivery methods for antisense oligonucleotides.
ONTY And CLDX Announce Initiation Of Immunotherapy Clinical Trials; NPSP Initiates Study Of Teduglutide
ONTY and CLDX announced they have initiated a combined clinical trial of ONT-10 and varlilumab. NPSP announced the company has initiated a global registration study of teduglutide in pediatric patients.
U.S. Stocks Switched Between Small Gains And Losses
With the main benchmarks hovering near record levels in the wake of a solid jobs report, a key payrolls data showed the economy added 214,000 jobs in October, while the unemployment rate ticked down to 5.8% — a broadly positive reading.
Biotech Stocks: The Sector's Most Comprehensive Immunotherapy Platforms
The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
The Dow And The S&P Both Hit New Intraday Highs
U.S. stocks were mixed in a quiet session Thursday as rising hopes about more stimulus in Europe were tempered by a continuing decline in oil prices.
ALNY Completes Phase 2 Enrollment; FDA Grants Orphan Drug Designation To MACK
Alnylam Pharmaceuticals announced it has completed enrollment in its Phase 2 clinical trial with revusiran.Merrimack Pharmaceuticals announced the U.S. FDA has granted orphan drug designation for the treatment of pancreatic cancer.
Q&A With Cell Source CEO, Itamar Shimrat – Transition From Preclinical To Human Clinical Trials
Recent breakthroughs from Cell Source in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants
AZN And PCYC Enter Clinical Trial Collaboration To Evaluate IMBRUVICA
AstraZeneca and Pharmacyclics will collaborate on a non-exclusive basis and multiple studies may be considered and conducted. The studies will be led by AstraZeneca.
Newsmakers: ISIS, ALQA, MLAB, HNT, ANIP
Stocks edged higher in afternoon trading Monday, with major indexes pushing deeper into record territory ahead of fresh economic updates this week.
Active Stocks: ABBV, DRAD, ZIOP, AEGR, SRPT
U.S. stocks surged Friday, with the Dow hitting an intraday record, joining a rally in Asian and European shares that was spurred by the Bank of Japan’s decision to unexpectedly expand its stimulus measures.
Movers: JNJ, PRGO, AZN, ACHC, CRL
U.S. stocks extended gains in afternoon trading, as a strong earnings report from Visa Inc. spurred a sharp advance in the Dow industrials.
Newsmakers: Gilead, Amedisys, Compugen, ICAD, Cara Therapeutics
U.S. stocks dipped and bonds slid after the Federal Reserve offered a brighter assessment of the U.S. job market, a shift that investors reckoned could bring forward the timing of interest-rate increases.
Active Stocks: Columbia Laboratories, Neurometrix, Cynosure, Receptos, Bristol-Myers
U.S. stocks climbed in afternoon trading on Tuesday, following stronger-than-expected earnings and an upbeat consumer confidence reading.
33 to 48 of 77 Posts